San Diego, CA--June 20, 2011--Mentor Capital, Inc. (Pink Sheets:MNTR) reports that Chinese visitors comprised 24% of views on its MentorCapital.com website covering leading-edge cancer development and investment. An equal proportion came from other worldwide locations. This increased international investor interest seems to correspond to Mentor Capital’s recent decision to expand its cancer-only investment activity to include promising cancer companies outside of the United States.

“There are bright minds in every country,” comments Mentor Capital, CEO, Chester Billingsley. “Often researchers are educated in the U.S. and continue some of their key cancer development work here. Any meaningful breakthrough quickly becomes international. If our shareholders are backing a German cancer vaccine, it will come to benefit patients in New York just as quickly as if it were developed in California.”

The technical diversity of new Mentor discussions from the international pool include an Israeli company that uses small unmatched donor infusions to trigger an aggressive cancer fighting immune response; an Italian company capturing and identifying minute traces of cancer cells on a silicon chip; and a Chinese company at the forefront of DNA screening to steer personalized cancer treatments.

“Another factor in the increased Mentor Capital international investment interest may be that holding shares in biotech companies may be becoming more attractive to the ‘return-free risk’ contemplated by foreign holders of U S. Treasuries. Whatever the reason, we will continue our worldwide search to align our shareholder’s investments behind the best new cancer solutions,” concludes Billingsley.

Mentor Capital currently holds $2.50 per Mentor share in cancer assets from twelve companies. Management seeks to weight its investments so that it’s socially responsible shareholders support the best medical science in the battle against cancer. Typical cancer investments can be tracked through updates and summaries of the several smaller stock purchases made for the Cancer Immunotherapy Index presented at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.


__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top